This is a non-insurance-covered form of peptide therapy for weight loss
Non-surgical care can improve texture and mild to moderate laxity, but it cannot remove large amounts of redundant tissue
Weight loss typically continues, with clinical trials showing that semaglutide 2.4 mg (Wegovy) produces average weight loss of approximately 15% by week 68, while tirzepatide (Zepbound) has demonstrated weight loss of approximately 15-21% across different doses by week 72
It can add context to a provider conversation about the GLP-1 pathway in general, but it does not set doses, select a medication, or predict response to retatrutide or any specific drug
These symptoms typically normalize within 10 to 14 days
You can find PCOS-friendly recipes, workout routines, resources, and support on The Cysterhood app to kick-start your journey